Ekblom Anders 4
4 · Mereo BioPharma Group plc · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Mereo BioPharma (MREO) Director Anders Ekblom Receives Award
What Happened
Anders Ekblom, a non‑executive director of Mereo BioPharma Group plc (MREO), received equity awards on Feb 26, 2026. The Form 4 reports two derivative awards totaling 199,560 shares (66,000 shares listed at $0.00 and 133,560 shares listed as N/A). These are deferred restricted stock units (DRSUs) granted as director compensation, not open‑market purchases or sales, and therefore represent routine compensation rather than an immediate bullish or bearish trade.
Key Details
- Transaction date: February 26, 2026; filing date: February 27, 2026 (reported timely).
- Awards: 66,000 shares @ $0.00 (derivative) and 133,560 shares @ N/A (derivative); total 199,560 ordinary‑share units.
- ADS equivalent: If paid in ADSs (per footnote), 199,560 ordinary shares = 39,912 ADSs (1 ADS = 5 ordinary shares).
- Vesting/payment: Vests in substantially equal monthly installments over one year from Feb 26, 2026. DRSUs elected to be paid in ADSs are generally paid 180 days after separation of service. (Footnotes F1–F3)
- Shares owned after transaction: Not specified in the filing.
- Nature of transaction: Award/grant (code A) — derivative units granted as director compensation, not an immediate stock purchase or sale.
Context
DRSUs are time‑based, deferred awards that convert into ADSs/ordinary shares later and are commonly used to compensate non‑executive directors. These grants are routine compensation and do not by themselves indicate the director is buying or selling shares in the market.
Insider Transaction Report
- Award
Share Options (Right to buy)
[F1][F2]2026-02-26+66,000→ 66,000 totalExercise: $0.39Exp: 2036-02-26→ American Depositary Shares (66,000 underlying) - Award
Deferred Restricted Stock Units
[F3][F2]2026-02-26+133,560→ 133,560 total→ American Depository Shares (133,560 underlying)
Footnotes (3)
- [F1]Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
- [F2]Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
- [F3]Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.